What drove ALCLS.PA stock lower after hours on 19 Mar 2026?

The after-hours dip to **€2.99** followed the earnings update and investor caution around clinical timelines and cash burn. Market reaction reflected negative EPS **-0.28** and ongoing R&D intensity rather than a single pricing shock.

What is Meyka AI's 12-month forecast for ALCLS.PA stock?

Meyka AI's forecast model projects a 12-month base price of **€5.60** for ALCLS.PA stock, implying an **87.29%** upside from **€2.99** today. Forecasts are model projections and not guarantees.

Which metrics should I watch for ALCLS.PA stock after earnings?

Focus on cash runway, clinical enrollment milestones for UCART programs, R&D burn, and guidance language. Watch EPS trends and liquidity ratios such as cash per share **€1.90** and current ratio **1.49**.

How does sector performance affect ALCLS.PA stock outlook?

As a biotechnology healthcare name listed on EURONEXT, ALCLS.PA stock is sensitive to sector flows and risk appetite for clinical-stage companies; biotech sentiment swings can amplify price moves regardless of company-specific news.

EU Stocks

€2.99 ALCLS.PA after hours 19 Mar 2026: Cellectis EURONEXT earnings outlook

ByDanny Kontos March 19, 2026March 19, 2026

ALCLS.PA stock fell to €2.99 in after-hours trade on 19 Mar 2026 after Cellectis S.A. published its earnings update. We saw an intraday decline of -4.17% on volume of 245,414 shares as investors parsed clinical progress and cash metrics. The company reports on EURONEXT for the Europe market and we are watching EPS -0.28 and guidance signals that could drive near-term volatility.